NCT04118842 - A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 17, 2019

Primary Completion Date

February 26, 2020

Study Completion Date

February 26, 2020

Conditions

Solid Tumors

Interventions

DRUG

Savolitinib

Patients will receive a single dose on Study Day 1 and Study Day 20. Savolitinib will be administrated after a high fat, high calorie breakfast to reduce the risk of adverse events.

DRUG

Rifampicin

Patients will receive Rifampicin once daily on Study Day 15, 16, 17, 18, 19, 20 and 21. Rifampicin will be administered 1 hour before breakfast.

Trial Locations (1)

21225

Research Site, Baltimore